Session: MON 796-817-Diabetes Genetics & Epidemiology
Poster Board MON-802
Objective: To investigate the association of the Asp299Gly and Thr399Ile polymorphisms, individually or in combination, with susceptibility to T2DM in a white Southeast Brazilian population.
Methods: We analyzed 748 patients with T2DM and 472 non-diabetic subjects. The local ethic committee approved the study, and all subjects signed an informed consent form. Polymorphisms were genotype by Real-Time PCR using TaqMan MGB probes (Life Technologies). Haplotypes constructed from the combination of Thr399Ile and Asp299Gly polymorphisms were inferred using Phase 2.1 program, which implements a Bayesian statistical method.
Results: Genotypes of both polymorphisms were in Hardy-Weinberg equilibrium. The frequency of the 399Ile (T) allele was higher in non-diabetic subjects as compared to T2DM patients (7% vs. 4%; OR=0.636, CI 95% 0.433-0.935). Moreover, T2DM patients carrying the T allele of this polymorphism had lower levels of fasting plasma glucose (FPG) than patients with the C/C genotype (152.0 ± 36.0 vs. 162.5 ± 64 mg/dl; P=0.031). The Asp299Gly (A/G) polymorphism was not significantly associated with T2DM (P=0.06); however, T2DM patients with the G/G genotype showed lower levels of FPG as compared to patients carrying the A allele (108.0 ± 28.2 vs. 173.1 ± 73.0 mg/dl; P=0.04). The 299Gly (G) /399Ile (T) haplotype was also associated with protection for T2DM (Permutation P=0.021) and with lower levels of FPG (P=0.026).
Conclusion: In our population, the TLR4 399Ile (T) allele and the 299Gly (G) /399Ile (T) haplotype are associated with a significant protection for T2DM as well as with lower FPG in T2DM patients.
Nothing to Disclose: TSA, NEL, LDAB, LHC, DC
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters